| Dr Michael J Mcgrath, MD | |
|
75-1091 Kamalani St, Holualoa, HI 96725-9646 | |
| (808) 334-4400 | |
| Not Available |
| Full Name | Dr Michael J Mcgrath |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 75-1091 Kamalani St, Holualoa, Hawaii |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760536759 | NPI | - | NPPES |
| 0000202721 | Other | HI | HMSA |
| 075459-08 | Medicaid | HI | |
| 0000202721 | Medicaid | HI | |
| 00G0202726 | Other | HI | HMSA BILLING NUMBER (KAISER) |
| 07545902 | Other | HI | ALOHA CARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | MD - 9172 (Hawaii) | Primary |
| Entity Name | Hawaii Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710945969 PECOS PAC ID: 7618880667 Enrollment ID: O20031106000625 |
News Archive
The ARTORG Center for Biomedical Engineering Research of the University of Bern is the recipient of a grant from JDRF, the leading global funder for type 1 diabetes research.
In a post on IntraHealth's "Global Health Blog," Rebecca Kohler, senior vice president of corporate strategy and development at IntraHealth, writes about an event held last week on the sidelines of the Democratic National Convention (DNC) that "focused on the vital role of women's health in foreign policy."
Sangamo BioSciences, Inc. announced today that data from research and preclinical programs focused on the development of zinc finger DNA-binding protein Therapeutics were described in fifteen presentations given by Sangamo scientists and collaborators at the 13th Annual Meeting of the American Society of Gene and Cell Therapy.
"Efforts to force the public hospital [in Atlanta, Ga.] to continue providing free dialysis treatment to a group of immigrants, most of them illegal, suffered a setback on Tuesday when a judge dismissed a lawsuit challenging the recent closing of the hospital's outpatient renal clinic," The New York Times reports.
Clovis Oncology, Inc., a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents, and Avila Therapeutics, Inc., a biotechnology company designing targeted covalent drugs, announced today an agreement for the development and commercialization of Avila's epidermal growth factor receptor (EGFR) mutant-selective inhibitor (EMSI) program, currently in pre-clinical development for the treatment of non-small cell lung cancer (NSCLC).
› Verified 7 days ago
| Entity Name | Stepstone Connect |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124536461 PECOS PAC ID: 6305252750 Enrollment ID: O20220901002892 |
News Archive
The ARTORG Center for Biomedical Engineering Research of the University of Bern is the recipient of a grant from JDRF, the leading global funder for type 1 diabetes research.
In a post on IntraHealth's "Global Health Blog," Rebecca Kohler, senior vice president of corporate strategy and development at IntraHealth, writes about an event held last week on the sidelines of the Democratic National Convention (DNC) that "focused on the vital role of women's health in foreign policy."
Sangamo BioSciences, Inc. announced today that data from research and preclinical programs focused on the development of zinc finger DNA-binding protein Therapeutics were described in fifteen presentations given by Sangamo scientists and collaborators at the 13th Annual Meeting of the American Society of Gene and Cell Therapy.
"Efforts to force the public hospital [in Atlanta, Ga.] to continue providing free dialysis treatment to a group of immigrants, most of them illegal, suffered a setback on Tuesday when a judge dismissed a lawsuit challenging the recent closing of the hospital's outpatient renal clinic," The New York Times reports.
Clovis Oncology, Inc., a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents, and Avila Therapeutics, Inc., a biotechnology company designing targeted covalent drugs, announced today an agreement for the development and commercialization of Avila's epidermal growth factor receptor (EGFR) mutant-selective inhibitor (EMSI) program, currently in pre-clinical development for the treatment of non-small cell lung cancer (NSCLC).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael J Mcgrath, MD 75-1091 Kamalani Street, Holualoa, HI 96725-1719 Ph: (808) 334-4400 | Dr Michael J Mcgrath, MD 75-1091 Kamalani St, Holualoa, HI 96725-9646 Ph: (808) 334-4400 |
News Archive
The ARTORG Center for Biomedical Engineering Research of the University of Bern is the recipient of a grant from JDRF, the leading global funder for type 1 diabetes research.
In a post on IntraHealth's "Global Health Blog," Rebecca Kohler, senior vice president of corporate strategy and development at IntraHealth, writes about an event held last week on the sidelines of the Democratic National Convention (DNC) that "focused on the vital role of women's health in foreign policy."
Sangamo BioSciences, Inc. announced today that data from research and preclinical programs focused on the development of zinc finger DNA-binding protein Therapeutics were described in fifteen presentations given by Sangamo scientists and collaborators at the 13th Annual Meeting of the American Society of Gene and Cell Therapy.
"Efforts to force the public hospital [in Atlanta, Ga.] to continue providing free dialysis treatment to a group of immigrants, most of them illegal, suffered a setback on Tuesday when a judge dismissed a lawsuit challenging the recent closing of the hospital's outpatient renal clinic," The New York Times reports.
Clovis Oncology, Inc., a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents, and Avila Therapeutics, Inc., a biotechnology company designing targeted covalent drugs, announced today an agreement for the development and commercialization of Avila's epidermal growth factor receptor (EGFR) mutant-selective inhibitor (EMSI) program, currently in pre-clinical development for the treatment of non-small cell lung cancer (NSCLC).
› Verified 7 days ago